Bristol-Myers Squibb cefadroxil patent
Executive Summary
Was infringed by Moleculon's Kalipharma unit, the New Jersey Federal Court rules June 15. The drug accounted for about one-fourth of Kalipharma's sales revenue, before the firm suspended its sale in May following an International Trade Commission decision barring import of the drug. Moleculon said it will appeal the patent decision. Zenith and Biocraft recently reached a settlement of regarding a similar patent suit brought by Bristol-Myers Squibb ("The Pink Sheet" April 2, T&G-12).
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.